Progeneer is a research-led biotechnology company located in South Korea with expertise in nanotechnology. As our name Progeneer indicates, we are pioneers in protein and gene focused on engineering life for the better. We harness nucleic acids engineering to express protein in a cell free environment and envision a new paradigm for manufacturing biotherapeutics. Our vaccine adjuvant platform employs lipid nanotechnology and will be the solution to better protecting the world against diseases. Together, these technologies will empower next generation therapeutics tailored to a single patient. Progeneer was founded in 2018 and currently has ~30 employees working on various technology platforms. The three main pillars of research are cell free protein synthesis (CFPS), individualized vaccine, and vaccine adjuvant. Progeneer’s CFPS is a groundbreaking technology that can be implemented in protein providing services or high-volume manufacturing of biotherapeutics. The technology involves a patented RNA hydrogel to rapidly synthesis proteins, even those that were hardly expressed in cell-based systems. Utilizing the CFPS platform, Progeneer can also provide truly individualized cancer vaccine in 4 weeks. Our cholesterol capped TLR7/8 adjuvant can be applied with the individualized cancer vaccine to mount a strong cell-mediated immune response with the least amount of toxicity. Due to its ability to induce strong cell-mediated response and controlled activation of the TLR7/8 pathway, our vaccine adjuvant can solve the unmet needs in vaccinations against infectious diseases and anticancer therapies. We also have additional patented technologies including an inhaled surfactant nanoparticle engineered to deliver negatively charged molecules, an innovative DNA gel electrolyte applicable as flexible storage device or supercapacitors, and non-PCR based molecular diagnosis technologies that enable visible detection of the targets.